Rosetta Genomics’ Diagnostic Program Update (NASDAQ:ROSG)

Rosetta Genomics (NASDAQ:ROSG) today announced an update regarding their colon cancer diagnostic program and said that Ayelet Chajut, Executive Vice President, R&D, Head of Molecular Biology will speak more about this program at the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS-VI). The conference will held from November 9 to November 11 in Hong Kong where they will present a new generation of molecular diagnostic markers that will help in the treatment and diagnosis of colon cancer. Rosetta Genomics is one of the leading molecular diagnostics companies that develops and commercializes molecular diagnostic products based on its proprietary microRNAs. The company is also developing and discovering early detection cancer screening products, including a colon cancer screening test. Rosetta Genomics have their labs in Philadelphia where they perform commercial molecular diagnostics tests in order to discover and develop new diagnostics markers.

During the update, Rosetta Genomics pointed out that colon cancer serum project is still in the early stage of development, and the company cannot provide any assurance that it will be successful in developing this product in its intended timeframe, or at all. Also the company cannot assure that the final product will effectively differentiate colon cancer from other types of cancers. However, the company has a commercial product called miRview that can identify around 25 types of cancer and help them work on the colon cancer alone. Rosetta Genomics also updated that they have identified the microRNA potential biomarkers on serum samples obtained from colon cancer patients in comparison to samples derived from control individuals. The company is still gathering more data for further validation and are constantly reviewing the behavior of microRNA in health individuals and comparing it with patients who are suffering from colon cancer.